疫苗接种与多发性硬化急性发作住院风险
该队列研究纳入法国国家健康数据库2007年1月1日至2017年12月31日诊断的多发性硬化患者106 523例,采用巢式病例交叉分析,比较接种疫苗后60天内因多发性硬化急性发作住院的风险。结果显示所有疫苗、百白破脊髓灰质炎b型流感嗜血杆菌联合疫苗、流感疫苗和肺炎球菌疫苗的调整比值比均无显著关联,但作者认为需进一步研究确认。
要点
- 接种任何疫苗后60天内因多发性硬化急性发作住院的调整比值比为1.00(95%CI 0.92-1.09)。
- 百白破脊髓灰质炎b型流感嗜血杆菌联合疫苗、流感疫苗和肺炎球菌疫苗的调整比值比分别为0.95、0.98和1.20,均无显著关联。
- 作者结论认为疫苗接种与多发性硬化急性发作住院风险无关,但需进一步研究确认。
核心结论
- 法国全国人群研究发现疫苗接种与多发性硬化急性发作住院风险无关,但考虑到疫苗亚型数量,需进一步研究确认这些结果。
研究设计与样本
- 队列研究,纳入2007年1月1日至2017年12月31日法国国家健康数据库诊断的多发性硬化患者106 523例,平均随访8.8年(标准差3.1年)。
- 采用巢式病例交叉分析,比较接种疫苗后60天内因多发性硬化急性发作住院的风险与接种前最多4个对照时间窗内的发作率。
主要发现
- 106 523例患者中35 265例(33.1%)在随访期间因多发性硬化急性发作住院,共54 036次多发性硬化相关住院。
- 接种任何疫苗后60天内因多发性硬化急性发作住院的调整比值比为1.00(95%CI 0.92-1.09)。
- 百白破脊髓灰质炎b型流感嗜血杆菌联合疫苗的调整比值比为0.95(95%CI 0.82-1.11)。
- 流感疫苗的调整比值比为0.98(95%CI 0.88-1.09)。
- 肺炎球菌疫苗的调整比值比为1.20(95%CI 0.94-1.55)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为考虑到疫苗亚型数量,需进一步研究确认这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Scientific literature is sparse about the association of vaccination with the onset of multiple sclerosis (MS) flare-ups. Immunization by vaccines of the entire population is crucially important for public health. OBJECTIVE: To evaluate the risk of hospitalization for severe MS flare-ups after vaccination in patients with MS. DESIGN, SETTING, PARTICIPANTS: This cohort study included patients diagnosed with MS between January 1, 2007, and December 31, 2017, who were included in the System of National Health Databases, a national health claims database in France. In a nested case-crossover analysis, cases were defined by vaccine exposure prior to the onset of hospitalization due to an MS flare-up, and flare-up rates were compared with those that occurred prior to vaccine exposure in up to 4 control time windows immediately preceding the at-risk time window (ie, the MS flare-up) for each patient. Data were analyzed from January 2022 to December 2022. EXPOSURE: Receipt of at least 1 vaccination, including the diphtheria, tetanus, poliomyelitis, pertussis, or Haemophilus influenzae (DTPPHi) vaccine, influenza vaccine, and pneumococcal vaccine, during follow-up. MAIN OUTCOMES AND MEASURES: The primary outcome was the risk of hospitalization for an MS flare-up after receipt of a vaccine. Adjusted odds ratios (AORs) and 95% CIs were derived using conditional logistic regression to measure the risk of hospitalization for an MS flare-up associated with vaccination. RESULTS: A total of 106 523 patients constituted the MS cohort (mean [SD] age, 43.9 [13.8] years; 76 471 females [71.8%]; 33 864 patients [31.8%] had incident MS and 72 659 patients [68.2%] had prevalent MS) and were followed up for a mean (SD) of 8.8 (3.1) years. Of these patients, 35 265 (33.1%) were hospitalized for MS flare-ups during the follow-up period for a total of 54 036 MS-related hospitalizations. The AORs of hospitalization for an MS flare-up and vaccine exposure in the 60 days prior to the flare-up were 1.00 (95% CI, 0.92-1.09) for all vaccines, 0.95 (95% CI, 0.82-1.11) for the DTPPHi, 0.98 (95% CI, 0.88-1.09) for the influenza vaccine, and 1.20 (95% CI, 0.94-1.55) for the pneumococcal vaccine. CONCLUSIONS AND RELEVANCE: A nationwide study of the French population found no association between vaccination and the risk of hospitalization due to MS flare-ups. However, considering the number of vaccine subtypes available, further studies are needed to confirm these results.
引用
- Grimaldi L, Papeix C, Hamon Y, et al. Vaccines and the Risk of Hospitalization for Multiple Sclerosis Flare-Ups. JAMA Neurol. 2023. PMID: 37669073. doi:10.1001/jamaneurol.2023.2968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。